Chimeric Antigen Receptor-T Cell (CAR-T Cell) Therapy in Advanced Renal Cell Carcinoma

With introduction of immunotherapy, the treatment of advanced renal cell carcinoma has undergone a substantial change. Immunotherapeutic agents including nivolumab, ipilimumab, pembrolizumab, have been introduced and approved for therapy of this life-threatening malignancy. Chimeric antigen receptor- T cells produced using adoptive cell transfer genetic engineering technology, have shown significant benefits over previous immunotherapies, but their toxicity profile needs to be carefully weighed. While they have shown significant benefit in hematological malignancies, their role in solid tumors has shown mixed results. Several clinical trials are ongoing to evaluate their safety and efficacy in several malignancies, including advanced renal cell carcinoma.

This paper reviews in brief the immunotherapy and CAR-T cell therapy in renal cell carcinoma.